Work on the core CDX antibody project with the Company's major pharmaceutical partner continues to progress with successful results achieved in further laboratory tests and with discussions ongoing as to its future development and funding. The separate development of a treatment for AML using HEMO-CAR-T has shown encouraging results to date and additional projects using the Company's ApbHC mice are under development.
My guess it will start moving later this morning, can't believe it still mkt cap £37m,with us licensing deals and $42m deals, also cash in the bank, mental